These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2186412)

  • 21. Mild cognitive impairment and preclinical Alzheimer's disease.
    Morris JC
    Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapeutic approaches to Alzheimer's disease.
    Schneider LS
    J Clin Psychiatry; 1996; 57 Suppl 14():30-6. PubMed ID: 9024334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Viewpoint on the methodology of drug trials affecting cognition of elderly patients].
    Allain H; Bernard PM; Dartigues JF; Dérouesné C; Dubois B; Hugonot L; Laurent B; Léger JM; Malauzat D; Michel B
    Encephale; 1994; 20(6):725-39. PubMed ID: 7875107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mild cognitive impairment: transition between aging and Alzheimer's disease.
    Petersen RC
    Neurologia; 2000 Mar; 15(3):93-101. PubMed ID: 10846869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mild cognitive impairment].
    Perneczky R; Alexopoulos P; Kurz A
    MMW Fortschr Med; 2004 Sep; 146(38):34-7. PubMed ID: 15532428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plurality of patterns of cognitive impairment in normal aging and in dementia].
    Joanette Y; Belleville S; Gely-Nargeot M; Ska B; Valdois S
    Rev Neurol (Paris); 2000 Sep; 156(8-9):759-66. PubMed ID: 10992120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychopharmacological strategies in the search for cognition enhancers.
    Sanger DJ; Joly D
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():70-4. PubMed ID: 2186417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's disease management.
    Rabins PV
    J Clin Psychiatry; 1998; 59 Suppl 13():36-8. PubMed ID: 9771829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer's disease, and vascular cognitive impairment.
    Lindeboom J; Weinstein H
    Eur J Pharmacol; 2004 Apr; 490(1-3):83-6. PubMed ID: 15094075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models of cognitive function.
    Decker MW
    Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and treatment of Alzheimer's disease.
    Grossberg GT
    J Clin Psychiatry; 2003; 64 Suppl 9():3-6. PubMed ID: 12934967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recognizing apathy in Alzheimer's disease.
    Lerner AJ; Strauss M; Sami SA
    Geriatrics; 2007 Nov; 62(11):14-7. PubMed ID: 17999565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical models for cognition enhancers.
    Costall B; Barnes JM; Hamon M; Müller WE; Briley M
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():85-8; discussion 89. PubMed ID: 2186420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early human trials in the assessment of cognition activators.
    Gamzu ER; Birkhimer LJ; Hoover T; Gracon ST
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():44-8. PubMed ID: 2186411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The development of behavioral tests to assess the effects of cognitive enhancers.
    Olton DS; Wenk L
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():65-9. PubMed ID: 2186416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2013; 33(3):547-658. PubMed ID: 23042218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.